MountainView Hospital and Sarah Cannon, the Cancer Institute of HCA Healthcare,  celebrated the 1-year anniversary of its blood and marrow transplant (BMT) services in Nevada on July 29, 2022. The Sarah Cannon Transplant & Cellular Therapy Program at MountainView Hospital is the only such program in the state of Nevada.

The 1-year anniversary will be celebrated today, which also mark’s the program’s 10th transplant since opening.

 Prior to the opening of the new service at MountainView, 100 percent of patients had to leave Nevada to seek these services. Patients now have the option to receive this specialized care close to home.

Patients with blood cancers such as leukemia, lymphoma or multiple myeloma may be recommended by their physician to undergo a blood and marrow transplant, which is sometimes referred to as a stem cell transplant or bone marrow transplant. 

“This past year has been exciting in the growth and development of the blood and marrow transplant at MountainView Hospital,” said Matthew Cova, MountainView’s interim Chief Executive Officer. “In partnership with Sarah Cannon, we have been able to treat patients with different blood cancers and at different stages with favorable outcomes, while reducing the burden on the patients and their families by providing this complex treatment close to home.”

Prior to the opening of the BMT program at MountainView, approximately 100 Nevada residents per year had to leave the state to obtain blood and marrow transplant care which can create financial burdens and stressors to the patient and family/caregivers. In bringing this complex care to the Nevada community, cost and burden to patients can be reduced while providing the most cutting-edge services close to home.

Two transplant and cellular therapy veterans lead the program at MountainView Hospital - Dr. Delva Deauna-Limayo as the BMT Clinical Program Medical Director and Dr. Shahram Mori as the Transplant and Cellular Therapy Clinical Program Medical Director. The program is expanding and will begin offering CAR T-Cell therapy this fall and allogeneic transplant in early 2023.

“Providing blood and marrow transplant options in our state is a privilege and we see each day the impact we are making on Nevadans. We look forward to providing even more complex blood cancer care therapies later this year,” said Dr. Mori. “We are also grateful for the partnership with our community oncologists that allow us to keep their patients close to home for this specialized care.”

The Sarah Cannon Transplant & Cellular Therapy Program at MountainView Hospital is part of the Sarah Cannon Transplant & Cellular Therapy Network, offering patients convenient, community-based access to complex blood cancer care including acute leukemia, blood and marrow transplantation, clinical trials and innovative therapies. The Network treats 1,400+ transplant and cellular therapy patients annually across its nine FACT/JACIE accredited programs in the United States and United Kingdom.

Patients and physicians who want to learn more about MountainView’s new program can call (702) 962-2106.